WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

Contributed by: PR Newswire

Tags

WuXi-Biologics

More Like This

WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers

WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates

WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics

PR Newswire associated0

Antengene and UCB Enter Global License Agreement for ATG-201, a CD19/CD3 Bispecific T-Cell Engager for Autoimmune Diseases

WuXi Biologics Ireland Facility Receives EMA Approval for Commercial Manufacturing of Innovative Biologic

WuXi Biologics Ireland Receives 2025 Operational Excellence in Life Sciences Award

PR Newswire associated0

Fapon Biopharma to Present Next-Generation CD3/TCR VHH TCE Platform at 19th Annual European Life Sciences CEO Forum

PR Newswire associated0

EnGeneIC Selects Global CDMO BioCina to Advance Their Ground-Breaking Cancer Treatment